The United States developed a new vaccine against melanoma

US scientists say the process of testing a new vaccine against melanoma (melanoma) has initially yielded encouraging results.

New vaccine against melanoma cell cancer

According to the Science magazine on April 2, the new vaccine increases the number and type of T-cells, a type of lymph that produces Lymphokine for the human body's immune system. public tumors.

The researchers decoded the genome of three terminal stage melanoma cancer patients and compared these gene sequences with healthy tissue samples to identify modified proteins. These proteins are known as new antigens, and only these new antigens affect cancer cells.

(Source: Washington University)

Next, researchers use computer programs and laboratory tests to identify and test new antigens that can stimulate the body's immune response to include in the composition of vaccine.

The next step is to inject the vaccine into the three patients mentioned above.

Previously, these patients had surgery to remove melanoma but did not prevent cancer cells from spreading to lymph nodes, indicating that melanoma cancer would recur.

Initial results showed good results and patients had no side effects . Therefore, the US Food and Drug Administration has allowed scientists to conduct phase 1 clinical trials on the bodies of six other patients.

According to the oncologist, Dr. Gerald Linette of the University of Washington, who led the study, although it is just beginning, this experiment is expected to become a new treatment.

According to the latest statistics, in 2014, about 76,000 Americans were diagnosed with melanoma skin cancer, of which 10,000 died.